Latest Chemokine Stories

MOUNTAIN VIEW, Calif., Jan. 28 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases. CCX168 is a highly potent and very selective compound that specifically targets the C5a receptor (C5aR), a component of the body's complement system and a potent driver of the inflammatory response associated with autoimmune diseases such as systemic lupus erythematosus, certain...

MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire/ -- ChemoCentryx, Inc., announced today that the Company has appointed Geoffrey M. Parker to the Company's Board of Directors, effective immediately. Mr. Parker is Chief Business Officer of InteKrin Therapeutics, Inc. and previously served as Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. From 1997 to 2009, Mr. Parker directed Goldman Sachs' West Region Healthcare Investment Banking practice, advising...

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire/ -- ChemoCentryx, Inc., today announced that the executive management team will participate in the 28th Annual J.P. Morgan Healthcare Conference being held January 11 through January 14 in San Francisco at the Westin St. Francis Hotel. Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, is scheduled to present an update of the company's pipeline progress and recent developments on Tuesday, January 12, 2010 at 4:30 p.m....

MOUNTAIN VIEW, Calif., Dec. 16 /PRNewswire/ -- ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA). CCX354 is a highly potent and selective antagonist of CCR1, a chemokine receptor that drives the recruitment of immune cells, such as monocytes and macrophages, associated with...

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time. "It...

Up-regulation of certain cytokines and chemokines (signaling molecules involved in the functioning of the immune system) can predict the development of rheumatoid arthritis (RA) three years before the onset of symptoms, according to the results of a new study presented today at EULAR 2009, the Annual Congress of the European League Against Rheumatism in Copenhagen, Denmark.The results of the study showed that up-regulation of certain cytokines (specifically Th1, Th2 and Treg) involved in the...

Development Candidate Triggers Milestone Payment from GlaxoSmithKline MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally bioavailable small molecule antagonist of the C5a receptor, CCX168, as a candidate for clinical development. The acceptance of the molecule as a development candidate triggered a $5.0 million milestone payment from the alliance with GlaxoSmithKline (NYSE: GSK). CCX168 is designed to specifically...

Trial to Evaluate Safety of CCL2-LPM for Inflammatory Kidney Disease SAN FRANCISCO, April 14 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., Inc. announced today that patient dosing has commenced in a Phase Ib clinical trial of the company's lead compound, CCL2-LPM, for the treatment of IgA nephropathy, an inflammatory kidney disease. Osprey Pharmaceuticals U.S.A. is developing novel chemokine-enzyme fusion protein therapeutics, known as Leukocyte Population Modulators (LPMs), for the...

An inflammatory factor already linked to several diseases, including pulmonary disease, lung cancer, and arthritis, may also be responsible for the insulin resistance that comes with obesity, according to a new study published in the April issue of Cell Metabolism, a Cell Press publication.Researchers have found that the inflammatory chemokine known as CXCL5 rises and falls with obesity and subsequent weight loss in humans. (Chemokines are structurally related signaling proteins that are...

Therapeutic Approach Provides HIV-Resistant Immune Cells RICHMOND, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS. Based on Sangamo's zinc finger DNA-binding protein nuclease (ZFN) technology, SB-728-T has been shown in an animal model of HIV infection to lead to an increase in CD4+ T-cell...